John DeLuca
Memorial Sloan Kettering Cancer Center
8 Papers
22 Citations
John DeLuca is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 6, co-authored 8 publications. Previous affiliations of John DeLuca include Cornell University.
Chat about Author
Papers
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo,Ana M. Molina,Yulia Lakhman,Sujata Patil,Kaitlin M. Woo,John DeLuca,Chung-Han Lee,James J. Hsieh,Darren R. Feldman,Robert J. Motzer,Martin H. Voss +10 more
TL;DR: BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.
97
Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
TL;DR: The Memorial Sloan‐Kettering Cancer Center risk model classifies patients with metastatic renal cell carcinoma by 5 pretreatment features as favorable, intermediate, and poor risk.
50
Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma
Darren R. Feldman,G. Varuni Kondagunta,Lawrence H. Schwartz,Sujata Patil,Nicole Ishill,John DeLuca,Paul Russo,Robert J. Motzer +7 more
TL;DR: Pegylated IFN administered weekly has antitumor activity in patients with mRCC with predominantly good- and intermediate-risk features with comparable efficacy and safety comparerd with standard IFN-α.
22
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
Premal H. Patel,G. Varuni Kondagunta,Lawrence H. Schwartz,Nicole Ishill,Jennifer Bacik,John DeLuca,Paul Russo,Robert J. Motzer +7 more
TL;DR: Lenalidomide is tolerable, but no objective responses were observed in this clinical trial of lenalidomides with metastatic renal cell carcinoma.
19
Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response
G. V. Kondagunta,Jennifer Bacik,Nicole Ishill,Victor E. Reuter,Lawrence H. Schwartz,James E. Korkola,John DeLuca,S. Sweeney,R. S. K. Chaganti,Robert J. Motzer +9 more
TL;DR: PEG-I treatment results in a 31% response rate and similar median time to progression as standard IFN in this population with predominantly good and intermediate risk pts, and once weekly dosing was generally well tolerated.
4